Cargando…
Spontaneous Pneumomediastinum and Bilateral Pneumothoraces in a Patient with Bleomycin-Induced Pneumonitis
Bleomycin lung toxicity is well established and can manifest as bleomycin-induced pneumonitis, but pneumomediastinum and pneumothorax are very rare complications. We report the case of a 73-year-old woman, recently treated with bleomycin for Hodgkin’s disease, who was admitted for bleomycin-induced...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SMC Media Srl
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6346796/ https://www.ncbi.nlm.nih.gov/pubmed/30755913 http://dx.doi.org/10.12890/2017_000727 |
_version_ | 1783389821580869632 |
---|---|
author | Barras, Matthieu Uhlmann, Marc |
author_facet | Barras, Matthieu Uhlmann, Marc |
author_sort | Barras, Matthieu |
collection | PubMed |
description | Bleomycin lung toxicity is well established and can manifest as bleomycin-induced pneumonitis, but pneumomediastinum and pneumothorax are very rare complications. We report the case of a 73-year-old woman, recently treated with bleomycin for Hodgkin’s disease, who was admitted for bleomycin-induced pneumonitis. Two weeks later she had a pneumomediastinum with extensive subcutaneous emphysema and small bilateral pneumothoraces. Three months after that she was readmitted for dyspnoea. The CT scan showed complete regression of the pneumomediastinum but extensive bilateral ground-glass infiltrates. The patient died from respiratory failure 2 weeks later. LEARNING POINTS: Respiratory investigation before initiation of bleomycin treatment and then close follow-up during treatment of any abnormalities found is mandatory, as bleomycin -induced toxicity can lead to fibrosis and secondary pneumothorax/pneumomediastinum with high morbidity/mortality. Bleomycin-induce pneumonitis (BIP) is managed with bleomycin discontinuation (Grade 1A) and system corticosteroid (Grade 1B). Supplemental oxygen is discouraged for BIP, but indicated for conservative management of pneumothoraces, so this case was managed with limited oxygen supplementation (aiming for oxygen saturation of 92–94%). |
format | Online Article Text |
id | pubmed-6346796 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | SMC Media Srl |
record_format | MEDLINE/PubMed |
spelling | pubmed-63467962019-02-12 Spontaneous Pneumomediastinum and Bilateral Pneumothoraces in a Patient with Bleomycin-Induced Pneumonitis Barras, Matthieu Uhlmann, Marc Eur J Case Rep Intern Med Articles Bleomycin lung toxicity is well established and can manifest as bleomycin-induced pneumonitis, but pneumomediastinum and pneumothorax are very rare complications. We report the case of a 73-year-old woman, recently treated with bleomycin for Hodgkin’s disease, who was admitted for bleomycin-induced pneumonitis. Two weeks later she had a pneumomediastinum with extensive subcutaneous emphysema and small bilateral pneumothoraces. Three months after that she was readmitted for dyspnoea. The CT scan showed complete regression of the pneumomediastinum but extensive bilateral ground-glass infiltrates. The patient died from respiratory failure 2 weeks later. LEARNING POINTS: Respiratory investigation before initiation of bleomycin treatment and then close follow-up during treatment of any abnormalities found is mandatory, as bleomycin -induced toxicity can lead to fibrosis and secondary pneumothorax/pneumomediastinum with high morbidity/mortality. Bleomycin-induce pneumonitis (BIP) is managed with bleomycin discontinuation (Grade 1A) and system corticosteroid (Grade 1B). Supplemental oxygen is discouraged for BIP, but indicated for conservative management of pneumothoraces, so this case was managed with limited oxygen supplementation (aiming for oxygen saturation of 92–94%). SMC Media Srl 2017-10-09 /pmc/articles/PMC6346796/ /pubmed/30755913 http://dx.doi.org/10.12890/2017_000727 Text en © EFIM 2017 This article is licensed under a Commons Attribution Non-Commercial 4.0 License (https://creativecommons.org/licenses/by-nc-nd/4.0/) |
spellingShingle | Articles Barras, Matthieu Uhlmann, Marc Spontaneous Pneumomediastinum and Bilateral Pneumothoraces in a Patient with Bleomycin-Induced Pneumonitis |
title | Spontaneous Pneumomediastinum and Bilateral Pneumothoraces in a Patient with Bleomycin-Induced Pneumonitis |
title_full | Spontaneous Pneumomediastinum and Bilateral Pneumothoraces in a Patient with Bleomycin-Induced Pneumonitis |
title_fullStr | Spontaneous Pneumomediastinum and Bilateral Pneumothoraces in a Patient with Bleomycin-Induced Pneumonitis |
title_full_unstemmed | Spontaneous Pneumomediastinum and Bilateral Pneumothoraces in a Patient with Bleomycin-Induced Pneumonitis |
title_short | Spontaneous Pneumomediastinum and Bilateral Pneumothoraces in a Patient with Bleomycin-Induced Pneumonitis |
title_sort | spontaneous pneumomediastinum and bilateral pneumothoraces in a patient with bleomycin-induced pneumonitis |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6346796/ https://www.ncbi.nlm.nih.gov/pubmed/30755913 http://dx.doi.org/10.12890/2017_000727 |
work_keys_str_mv | AT barrasmatthieu spontaneouspneumomediastinumandbilateralpneumothoracesinapatientwithbleomycininducedpneumonitis AT uhlmannmarc spontaneouspneumomediastinumandbilateralpneumothoracesinapatientwithbleomycininducedpneumonitis |